NCT Number: NCT05682443
Phase: PHASE1|PHASE2
Trial Summary: The goal of this clinical trial is to examine the safety and efficacy of ONC-392 in combination with lutetium Lu 177 vipivotide tetraxetan in metastatic castration resistant prostate cancer patient wh – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): OncoC4, Inc.
Acronym: PRESERVE-006
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives